Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASKG915 as a Single Agent in Patients with Selected Advanced Solid Tumors
Study of ASKG915 in Patients with Advanced Solid Tumors
Sponsor: AskGene, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAU6331
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: The purpose of this study is to test the safety and effectiveness of ASKG915 at different dose levels to find out what effects, good or bad, this study drug has on you and your cancer. ASKG915 is an experimental treatment that is being developed for treating people with advanced solid tumors. Experimental means the study drug has not been approved for the treatment of participants with cancer by the Food and Drug Administration (FDA) or any other health/regulatory authority anywhere in the world. This is the first time ASKG915 is being tested in humans. Cancers include: bladder cancer, colon and rectal cancer, esophageal cancer, cervical cancer, ovarian cancer, head and neck/oral cancer, lung cancer, and testicular cancer.
This study is closed
Mark Stein, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Is your life expectancy greater than 3 months? Yes No
Have you had major organ surgery? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator